Last-Resort leukemia drug made available to 29 patients
NCT ID NCT07517315
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides continued access to the drug vodobatinib for people with Philadelphia chromosome-positive chronic myeloid leukemia (CML) whose cancer has not responded to prior treatments. After the main study was stopped early for non-safety reasons, 29 patients who were still benefiting from the drug were allowed to keep receiving it. Their care is managed by their own doctors according to local standards.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vodobatinib
- What this could lead to
- If successful, this could provide a treatment option for people with chronic myeloid leukemia who have not responded to other therapies.
- What could go wrong
- This is an expanded access program, not a formal trial, so results are limited. The main study was stopped early, and only 29 patients are included.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CML, REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Colentina Clinical Hospital
Bucharest, Romania
-
Georgia Cancer Center at Augusta University
Augusta, Georgia, 30912, United States
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
IRCCS Romagnolo Institute for the Study of Tumors "Dino Amadori"
Meldola, FC, 47014, Italy
-
Léon Bérard Center
Lyon, 69373, France
-
Meenakshi Mission Hospital and Research Centre
Madurai, India
-
Oncology Institute "Prof. Dr. Ion Chiricuță"
Cluj-Napoca, Romania
-
Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer
Navi Mumbai, India
-
University of Debrecen, Clinical Center Institute of Internal Medicine
Debrecen, 4032, Hungary
-
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States